TGFB2 and esophageal squamous cell carcinoma: In summary, these results declare that the combined targeting of tRF‐22 and TGFβ2 reduces PMN‐MDSCs infiltration, alleviates CD8+ T cells suppression, and improves the ICB efficacy in ESCC.